Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken
Aandeel

Novacyt FR0010397232

Laatste koers (eur)

0,830

  • Verschill

    +0,080 +10,67%

  • Volume

    1.517.074 Gem. (3M) 170,3K

  • Bied

    -  

  • Laat

    -  
+ Toevoegen aan watchlist

nieuws Novacyt

219 Posts
Pagina: «« 1 ... 6 7 8 9 10 11 »» | Laatste | Omlaag ↓
  3. forum rang 10 voda 19 maart 2022 13:38

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Nog wat aankopen van Novacyt directeurs:

    Novacyt S.A.

    ("Novacyt" or the "Company")

    Director/PCA Dealing

    Paris, France and Camberley, UK – 1 8 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 18 March 2022 that Jean - Pierre Crinelli, a Non - Executive Director of Novacyt, acquired 3,208 ordinary shares in the Company at a price of €2.41 per share. Following the transaction, Mr Crinelli is interested in 33,981 ordinary shares representing 0.05% of the
    issued share capital.

    In addition, the Company has been notified that Sylvie Dugat , a person closely associated ( “ PCA ” ) to Jean - Pierre Crinelli, has purchased 5,800 ordinary shares in the Company at a price of €2.58 per share.

    Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

    Voor meer, zie link:

    novacyt.com/2022/03/18/director-pca-d...
  4. forum rang 10 voda 26 maart 2022 08:18

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    18/03/22Posted in Board, Novacyt Group, Products, Uncategorized

    Director/PCA Dealing

    Paris, France and Camberley, UK – 18 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 18 March 2022 that Jean-Pierre Crinelli, a Non-Executive Director of Novacyt, acquired 3,208 ordinary shares in the Company at a price of €2.41 per share. Following the transaction, Mr Crinelli is interested in 33,981 ordinary shares representing 0.05% of the issued share capital.

    novacyt.com/wp-content/uploads/2022/0...
  5. forum rang 10 voda 12 april 2022 08:09

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    12/04/22Posted in Board, Novacyt Group, Products, Uncategorized

    Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation

    Paris, France and Camberley, UK – 12 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate® COVID-19 1G (q32) Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).

    novacyt.com/wp-content/uploads/2022/0...
  6. forum rang 10 voda 20 april 2022 08:16

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    20/04/22Posted in Board, Novacyt Group, Products, Uncategorized

    Notice of Full Year 2021 Results and Investor Presentation

    Paris, France and Camberley, UK – 20 April 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2021 on Thursday, 28 April 2022.

    novacyt.com/wp-content/uploads/2022/0...
  7. forum rang 10 voda 26 april 2022 09:08

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with the Department of Health and Social Care (“DHSC”).

    On 9 April 2021, Novacyt announced it was in dispute with the DHSC regarding its second supply contract, announced on 29 September 2020. On 25 April 2022, the Company was notified that the DHSC has now issued a claim against Primerdesign Ltd and Novacyt S.A. for £134.6m relating to this contract. The claim amount is broadly in line with the disputed Q4 2020 revenue, as previously announced by the Company.

    The Company continues to believe it has strong grounds to defend the claim and assert its contractual rights, including in relation to recovering outstanding sums due from the DHSC.
    The Company is unable to provide further comment at this time due to the ongoing nature of this claim but will provide further updates as appropriate.

    novacyt.com/wp-content/uploads/2022/0...
  8. forum rang 10 voda 28 april 2022 08:07

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    28/04/22Posted in Board, Novacyt Group, Products, Uncategorized

    Full year 2021 results and update on growth strategy

    Full year revenue and EBITDA in line with market expectations despite challenging and changing COVID-19 testing market
    Leveraging core capabilities to become a leading, global clinical diagnostics company targeting annual revenues in excess of £100m in five years

    novacyt.com/wp-content/uploads/2022/0...
  9. forum rang 10 voda 13 mei 2022 08:12

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Notice of Annual General Meeting

    Paris, France and Camberley, UK – 13 May 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (“AGM”) will be held at 2pm CEST/1pm BST on 21 June 2022 as an open virtual meeting. Further details of the AGM will be provided to shareholders in due course.

    novacyt.com/wp-content/uploads/2022/0...
  10. forum rang 10 voda 1 juni 2022 08:10

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    01 Jun CTDA approval of PROmate® COVID-19 1 Gene and grant of CE mark for COVID-19 lateral flow self-test

    Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2021 has been published and uploaded to the Company’s website. The Annual Report has been posted to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs).

    The Company’s Annual General Meeting (“AGM”) will be held as an open online meeting at 1pm BST/2pm CEST on Tuesday, 21 June 2022. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.

    The Notice of AGM and a Form of Proxy are available on the Company’s website, together with AGM registration details and a video explaining the voting process to shareholders. All materials can be found at www.novacyt.com/investors.

    Shareholders can register for the AGM and access the online meeting by visiting novacyt.eventcaster.co.uk. Registrations must include an electronic signature and be accompanied by proof of shareholding by 10.59pm BST/11.59pm CEST on Thursday 16 June 2022.

    Shareholders are strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the Notice of AGM

    Voor meer, zie link:

    novacyt.com/ctda-approval-of-promate-...

    novacyt.com/wp-content/uploads/2022/0...
  11. forum rang 10 voda 13 juni 2022 08:11

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Novacyt S.A.
    ( “ Novacyt ” , the “ Company ” or the “Group” )
    AGM voting

    Paris, France and Camberley, UK – 1 3 June 20 2 2 – Novacyt (EURONEXT GROWTH:
    ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its
    annual general meeting (AGM) as an open online meeting at 2pm CEST/1pm BST on 21
    June 2022 . A s usual, and in accordance with French corporate law, the AGM comprises
    both ordinary and extraordinary general meetings.

    Under French law, for the meetings to be quorate at the first attempt, at least 20% of the
    shareholders must vote on the ordinary resolutions and 25% of the shareholders must
    vote on the extraordinary resolutions. Shareholders are therefore strongly encour aged to
    submit their proxy votes either by post, email or vote electronically in accordance with the
    instructions in the notice convening the meeting, copies of which are available in the
    General Meetings section on the Company’s website at www.novacyt.com/investors .

    Following registration and proof of share holding, shareholders will be able to virtually
    attend the AGM and vote online during the meeting if they wish. Following the meeting, a
    recording of the AGM will be available on the Company’s website at
    www.novacyt.com/investors . Shareholders who have al ready voted (through a proxy,
    using the AGM or Votaccess portals) will be allowed to attend the AGM but will not be able
    to vote twice.
    - End

    novacyt.com/wp-content/uploads/2022/0...
  12. forum rang 10 voda 16 juni 2022 08:11

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with the Department of Health and Social Care (“DHSC”).

    On 25 April 2022, the Company was notified that the DHSC had issued a claim against Primerdesign Ltd and Novacyt S.A. for £134.6m in relation to the contract dispute announced by the Company on 9 April 2021 regarding its second supply contract with the DHSC, announced on 29 September 2020.

    On 15 June 2022, the Company filed a defence of the claim received on 25 April 2022 and a counterclaim of £81.5m against the DHSC. The value of the counterclaim is broadly in line with the amounts previously announced by the Company in its full year 2020 results, plus related interest.

    The Company continues to believe it has strong grounds to defend the claim and assert its contractual rights, including recovering outstanding sums due from the DHSC under the counterclaim.
    Unfortunately, the Company is unable to provide further comment at this time but will provide further updates as appropriate and to the extent permitted to do so.

    novacyt.com/wp-content/uploads/2022/0...
  13. forum rang 10 voda 21 juni 2022 17:21

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    21 Jun Notice of rescheduled AGM
    in Board, News, Novacyt Group, Products, Uncategorized

    Paris, France and Camberley, UK – 21 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (AGM), due to take place earlier today, will be rescheduled and held on Wednesday 20 July at 10am BST/11am CEST.

    To function as a procedural meeting, the AGM requires a sufficient number of shareholders to constitute a quorum to ensure the AGM is validly held in accordance with French corporate law. This threshold has not been met and, in accordance with Article 19 of Novacyt articles of association, the AGM has been rescheduled.

    novacyt.com/wp-content/uploads/2022/0...

    De link geeft meer informatie.
  14. forum rang 10 voda 28 juni 2022 08:14

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Launch of monkeypox assay

    Paris, France and Camberley, UK – 28 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of its research-use-only (RUO) polymerase chain reaction (PCR) monkeypox assay in response to the recent outbreak of the virus in non-endemic countries. The launch of this assay expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the Company’s strategy to maintain its position as a global first responder in infectious diseases.

    Monkeypox is a rare viral disease, which predominantly occurs in Central and Western
    Africa. The monkeypox virus is zoonotic meaning transmission is primarily between
    animals and humans, but human-to-human transmission can also occur, through contact
    with skin lesions, body fluids and respiratory secretions of infected animals or humans.
    Clinical presentations in humans are similar to smallpox with fever, headache, swollen
    lymph nodes, fatigue, and muscle aches along with characteristic pox lesions.

    Novacyt’s RUO monkeypox assay has been developed in two forms, genesig® easy and
    genesig® advanced, for detection of the virus genome (both West African and Central
    African variants). Both forms analyse DNA extracted from serum, lesion exudate, or scab
    samples from human or animal species. The genesig® advanced assay is designed to be
    used with any open test platform, including Novacyt’s MyGo instruments, whilst the
    genesig® easy assay is suitable for use on the Company’s q16 and q32 instruments. The
    advanced assay is quantitative if run alongside the recommended standard curve but can
    also be run without one and still give a qualitative result. The easy kit (q16 and q32 only)
    does not need a standard curve, instead software analyses the results of the sample and
    control to give a semi-quantitative result.

    David Allmond, Chief Executive Officer of Novacyt, commented:
    “Our RUO monkeypox assay has been developed in response to the recent outbreak of the virus in non-endemic countries and built around robust design principles and our real-time bioinformatics surveillance to monitor new monkeypox genome sequences. Whilst the risk of transmission of the disease to humans currently remains low, we believe our RUO assays are important tools to assist scientists and clinicians diagnose and monitor emerging infectious disease threats. The launch of this new assay further demonstrates Novacyt’s strength as a global first responder, in line with our strategy, as well as our commitment to expanding our portfolio in infectious disease.”

    novacyt.com/wp-content/uploads/2022/0...
  16. forum rang 10 voda 5 juli 2022 14:28

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Novacyt S.A.

    ("Novacyt" or the "Company")

    Holdings in Company

    Paris, France and Camberley , UK – 5 July 202 2 – Novacyt S.A. (EURONEXT GROWTH:
    ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it
    was notified by Biosynex SA (“Biosynex”) on 4 July 2022 that, as at 4 July 2022, Biosynex's
    holding in the Company on a voting and capital basis is 4.49 % ( 3 ,167,988 shares).
    For further information, please refer to www.novacyt.com or contact:

    novacyt.com/wp-content/uploads/2022/0...
  17. forum rang 10 voda 7 juli 2022 08:32

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Trading update and progress against strategy for H1 2022
    in Board, News, Novacyt Group, Uncategorized

    Paris, France and Camberley, UK – 7 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces a trading update for the half year ended 30 June 2022 and provides an update on delivery against its strategy as announced at the time of the full year 2021 results on 28 April 2022.

    novacyt.com/wp-content/uploads/2022/0...
  18. forum rang 10 voda 7 juli 2022 18:20

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Novacyt S.A.

    ("Novacyt" or the "Company")

    Director/PDMR Shareholding

    Paris, France and Camberley, UK – 07 July 2022 – Novacyt (EURONEXT GROWTH:
    ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has
    been notified that, on 07 July 2022, the following Director purchased ordinary shares of €1/15
    each in the Company (the “Ordinary Shares”):

    Voor meer, zie link:

    novacyt.com/wp-content/uploads/2022/0...
  19. forum rang 10 voda 15 juli 2022 08:11

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation
    in Board, News, Novacyt Group, Uncategorized

    Paris, France and Camberley, UK – 15 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s exsig™ COVID-19 Direct Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).

    Voor meer, zie link.

    novacyt.com/wp-content/uploads/2022/0...
  20. forum rang 10 voda 20 juli 2022 16:54

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 81741

      Gegeven: 20855

    •    Aantal posts: 364.021

    Novacyt S.A.
    ("Novacyt" or the "Company")
    Results of AGM

    Paris, France and Camberley, UK – 20 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM:
    NCYT), an international specialist in clinical diagnostics, announces that all resolutions proposed at
    the ordinary general meeting part of the Company’s Annual General Meeting (AGM), held today, were
    duly passed.

    As part of the AGM, the Company also met today to hold an extraordinary general meeting. The
    meeting was not deemed quorate due to the minimum number of voting rights under French company
    law not being present or represented at the meeting. Consequently, the meeting did not take place.
    The results of the AGM voting will be made available on the Company's website.

    novacyt.com/wp-content/uploads/2022/0...
219 Posts
Pagina: «« 1 ... 6 7 8 9 10 11 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Word abonnee

Laatste Nieuws

  1. Tech zet Wall Street lager richting weekend
  2. Olieprijzen dalen op weekbasis ondanks spanningen Midden-Oosten
  3. Europese beurzen terughoudend het weekend in
  4. Brussel sluit toch licht hoger
  5. Aandeel Super Micro Computer hard onderuit
  6. Beursagenda: Belgische bedrijven
  7. Meer omzet en winst voor Schlumberger
  8. Wall Street koerst af op vlakke opening
  9. Solvay onderuit op rode beurs
  10. Winst American Express stijgt harder dan omzet
  11. Procter & Gamble verhoogt outlook
  12. Europese beurzen lager rond middaguur

Meest Gelezen Premium

  1. Premium Premium
    Is Just Eat Takeaway ondergewaardeerd?
  2. Premium Premium
    Vooruitblik: aftrap cijferseizoen, einde bankenfeestje en CVC naar het Damrak
  3. Premium Premium
    Ingaan of niet op het bod op de Rabobank Certificaten?
  4. Premium Premium
    Vooruitblik eerstekwartaalcijfers ASML
  5. Premium Premium
    Orderintake ASML doet even pijn, maar verandert dit iets aan de beleggingscase?
  6. Premium Premium
    Energie-expert Jilles van den Beukel: "Je moet niet raar opkijken als Shell wordt overgenomen"
  7. Premium Premium
    Jitse Groen: ‘Het is niet gek dat er interesse is om ons van de beurs te halen’

Macro & Bedrijfsagenda

  1. 22 april

    1. NL investeringen februari
    2. SAP Q1-cijfers
    3. NL consumentenvertrouwen april
    4. NL prijzen bestaande koopwoningen maart
    5. ING jaarvergadering
    6. VS Chicago Fed-index maart
    7. EU consumentenvertrouwen april (voorlopig)

  2. 23 april

    1. Japan samengestelde inkoopmanagersindex april
    2. Novartis Q1-cijfers
    3. Renault Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda